Phase II study shows novel immunotherapy is safe in prostate cancer

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Pfizer announced positive topline results from the phase III TALAPRO-3 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in people with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Researchers “turbocharge” immune cells to attack prostate cancer

A team of researchers engineered a new class of “turbocharged” T cells that may be stronger, longer-lasting, and more precise at killing prostate cancer cells. The approach represents a step toward developing safer, more effective T-cell therapies for prostate cancer and could potentially be adapted to treat a wide range of other tumors.

March 27, 2026

Vol.52 No.12

Funding Opportunities

SITC seeks applications for two fellowships

Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding.

March 20, 2026

Vol.52 No.11

Guest Editorial

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially for those with very low PSA levels before treatment.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Phase II study shows novel immunotherapy is safe in prostate cancer

YOU MAY BE INTERESTED IN

Talzenna + Xtandi significantly improves radiographic PFS in metastatic prostate cancer

Researchers “turbocharge” immune cells to attack prostate cancer

SITC seeks applications for two fellowships

As more people are surviving cancer, we must continue funding bold science

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Renew today!

Subscriber content

Never miss an issue!

Login